Low-dose Atropine for Myopia Control in Children
A legfontosabb adatok
- Ki végzi
- University Eye Hospital, Freiburg
- Hol
- Németország19 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- NCT03865160
- EudraCT 2020-001575-33
- DRKS00023337
- Állapot
- Fut, nem toboroz
- Fázis
- 2/3. fázis
- Résztvevők
- 302 fő vett részt
- Kezdés
- 2021. okt. 19.
- Várható befejezés
- 2027. nov.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Atropine eye drops, 0.01%
- Atropine eye drops, 0.02%
- Placebo (NaCl 0.9%) eye drops
- A regiszteradat frissítve
- 2025. március 6.
Ki vehet részt
- Életkor
- 8 év – 12 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female patients aged 8 to 12 years (up to the day before the 13th birthday)
- Myopia of -1 D to -6 D with reported or documented annual progression ≥ 0.5 D of myopia
- Written informed consent obtained from patient (if applicable) and parents or legal guardians according to international guidelines and local laws
- Ability to understand the nature of the trial and the trial related procedures and to comply with them
Ki nem vehet részt
- Previous use of any kind of contact lenses
- Previous use of atropine eye drops
- Participation in any other interventional clinical trial within the last 30 days before the start of this trial
- History of amblyopia
- Any acquired or developmental organic eye disease
- Any known systemic metabolic disease or chromosomal anomaly
- Epilepsy
- Known hypersensitivity to the active substances or any of the excipients
- Caution and pediatric counselling shall be assured if any of the following conditions are present according to the Summary of Product Characteristics (SmPC): Cardiac insufficiency, arrhythmia, coronary stenosis, hyperthyroidism, stomach or bowel stenosis, bowel paralysis, megacolon, muscle weakness, lung edema, hypersensitivity to atropine, spastic paralysis
- Asian or African origin
- Abnormal binocularity
- Strabismus
- Astigmatism >1.5 D
- Anisometropia >1.5 D
- Corrected visual acuity in any eye <0.63
- Premature birth
- Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registries and diagnostic trials is allowed
- Contraindications according to the Summary of Product Characteristics (SmPC): Increased intraocular pressure (primary forms of glaucoma or narrow angle glaucoma), chronic rhinitis sicca
- Parents or children with poor understanding of the German language
- Person who is in a relationship of dependence/employment with the sponsor or the investigator
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Myopia (nearsightedness) is the most common eye disorder. Only second to age, it is the main risk factor for major degenerative eye diseases such as glaucoma, macular degeneration or retinal detachment. Their risk increases with the degree of myopia. Hence, prevention of myopia and slowing its progression is of high relevance. Almost all clinical studies, including two large randomised clinical trials (RCT) were performed in Asia with Asian study participants. The results indicate that atropine eye drops can attenuate myopic progression in children, even in low concentrations thus minimizing unwanted side effects. However, the cumulative evidence is yet not strong enough to recommend their unrestricted use, especially in a Non-Asian population. We therefore intend to set up an adequately powered RCT comparing atropine 0.02% eye drops with placebo to validate previous findings and to test whether this therapeutic concept holds its promise in a European population.
A vizsgálat 2 csoportja
- Arm A, Interventional groupA vizsgált kezelés
Treatment period 1: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.02%, 1 drop/eye, daily for 12 months Treatment period 3: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months
Kezelés: Atropine eye drops, 0.02% és Placebo (NaCl 0.9%) eye drops
- Arm B, Control groupA vizsgált kezelés
Treatment period 1: Placebo (NaCl 0.9%) eye drops, 1 drop/eye, daily for 12 months Treatment period 2: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months Treatment period 3: Atropine eye drops, 0.01%, 1 drop/eye, daily for 12 months
Kezelés: Atropine eye drops, 0.01% és Placebo (NaCl 0.9%) eye drops
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Low-dose Atropine for Myopia Control in Children, a Prospective, Double-blind, Placebo-controlled, Multicentric, Randomized Clinical Trial
- Publikációk
- A regiszteradat frissítve
- 2025. március 6.